Vaxil Bio Ltd., of Toronto, hired Barcelona-based BCN Peptides SA to manufacture a new batch of its lead candidate, Immucin (VXL-100), intended for use in the company's upcoming trials, including multiple myeloma and/or solid tumor indications.